A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for ...
This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. June 3, ...
When it comes to biologics like Rituxan and Remicade, which are intravenous infusions, decision making can be impacted by cost. Dr Fendrick asked the panelists what might hypothetically happen if cost ...
Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...
MALVERN, Pa.--(BUSINESS WIRE)--Dec. 20, 2004--Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved REMICADE(R) (infliximab) for the treatment of ankylosing ...
LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results